1.0 Tesla MRI Images Comparison to 9.4 Tesla
Ananth Annapragada, PhD, Professor of Radiology and Director of Basic Research in the Edward B. Singleton Department of Pediatric Radiology at Texas Childrens Hospital presents at the recent Human Placenta Project at NIH .
Prof. Annapragada provides data comparing Aspect 1.0 Tesla MRI images with data from a competitors high field 9.4 Tesla.
The Aspect 1.0T image data shows the exquisite high quality research that can be performed at lower fields and that for certain experiments higher field is not necessary.
Ananth Annapragada, Ph.D.
Director of Basic Research, Edward B. Singleton Department of Pediatric Radiology, Texas Children’s Hospital
New applications including multi-modal PET/MR imaging using the Bruker ICON™ Compact High-Performance MRI system
PET/MRI is an emerging field in medical research. We evaluated the potential of the ICON compact MRI system within a combined PET/MRI setup and provide various examples for in vivo PET/MRI studies. Application examples include cardiovascular disease, inflammation and arthritis and cancer biology in vivo. The unique attributes of this compact, high-performance MRI system – – with no external magnetic field and the possibility for placement anywhere in a biological lab – – will be discussed as a biological imaging tool, as well as a flexible instrument in a multi-modality imaging core facility.
Multi-Modality, Cancer, Cardiology, Inflammation, PET – MRI, PET/MRI, Arthritis
Multi-Modality, Cancer, Cardiology, Inflammation, Arthritis
Laboratory for Preclinical Imaging and Imaging Technology, Werner Siemens-Foundation Eberhard Karls University, Tuebingen
High-throughput Imaging Using Preclinical MRI
Compact, desktop MRI systems enable biologists to benefit from the 3D morphological imaging benefits of MRI without the cost, complexity and expertise required to operate high-field superconducting MRI systems. Dr. Johnson details many of these benefits and provides specific details on the use of the M2 compact high-performance MRI system for longitudinal studies of mice models of Human Colorectal Carcinoma and Glioblastoma.
NOTE: This presentation described the Aspect Imaging M2™ compact high-performance MRI system. The system is now available as the Bruker ICON, the standard in pre-clinical compact MRI platforms. The ICON uses Aspect Imaging’s compact magnet, gradients and animal handling systems.
Cancer, Neurology, Human Colorectal Carcinoma, Glioblastoma
G. Allan Johnson, Ph.D.
Director, Center for In Vivo Microscopy Charles E. Putman Distinguished Professor of Radiology, Professor of Biomedical Engineering and Physics Duke University, NC
MRI of tumors in mice at 1 and 7 Tesla with Gadolinium: When the low field is better!
Compact MRI at 1 Tesla have many advantages over high-field superconducting MRI but a key imaging benefit is the increased sensitivity for gadolinium-based contrast imaging. This talks explores the many techniques of MR-based contrast imaging including DCE (dynamic contrast-enhanced imaging) which detects and measures enhancement patterns to reflect tumor perfusion and permeability, angiography, vascular changes induced by anti-angiogenic vaccination, Fibrin accumulation in the extravascular compartment of tumor and MRI detection of tumor cells by targeting LDL (Low Density Lipoproteins) receptors with Gd-loaded LDL particles. All contrast imaging is performed on the M2™ compact, high-performance desktop MRI system (Aspect Imaging) and enables the benefit of increased sensitivity of Gd-based contrast agents.
NOTE: This presentation described the Aspect Imaging M2™ compact high-performance MRI system. The system is now available as the M5 compact high-performance MRI system.
Silvio Aime, Ph.D.
DHead, NMR Laboratory of the Department of Chemistry, University of Turino, Italy, Head, Centre of Excellence for Molecular Imaging Turino, Italy
Integrating Compact MRI into Multi-Modal Imaging Research for Cancer
While valuable as independent tools, imaging scanners can be coupled together in research applications to provide a richer understanding of the anatomical, functional, and molecular mechanisms driving disease and drug efficacy. The work associated with these experiments must add value to the project without crippling experiment throughput. Dr. Silva will explore the value of compact MRI integrated into multi-modal laboratory with emphasis on bioluminescence and nuclear medicine examples.
Cancer, Multi-Modality, Drug Development, LumiQuant, Bioluminescence
Cancer, Multi-Modality, Drug Development
Matt Silva, Ph.D.
Director, Imaging Research, InviCRO
Former Imaging Director of Research, Amgen (Thousand Oaks, CA) and Head of Imaging Sciences, Millennium Pharmaceuticals (Boston, MA)
Imaging & Intervention in Pre-Clinical Animal Models Using Compact MRI
Dr. Jaffray will discuss the approach of the multi-disciplinary STTARR Facility in Toronto, Canada in how it integrates imaging and intervention from a radiological and pharmaceutical perspective including image-guided drug delivery. Specifically, Dr. Jaffray will review how his research leverages the ICON compact MRI system within the context of multi-modality imaging to better understand and guide radiation therapy.
Multi-Modality, Image-guided radiation therapy, drug development
David A. Jaffray, Ph.D.
Head of Radiation Physics, Princess Margaret Hospital Senior Scientist, Ontario Cancer Institute Professor, Departments of Radiation Oncology, Medical Biophysics, University of Toronto, ON
Evaluation of Mouse Tumor Models Using Compact MRI
The development of compact MRI technology has increased the accessibility of this modality for cancer researchers interested in experimental therapeutics. In order to assess the utility of compact MR for use in this setting, several tumor models were evaluated using a variety of imaging sequences, including genetically engineered models of pancreatic cancer, bladder cancer, prostate cancer, glioma, and others. Dr. Olive will review the results of 3D tumor volume reconstructions to monitor response to therapy, as well as contrast imaging applications.
Cancer, Pancreatic Cancer, Therapeutic Response
Cancer, Pancreatic Cancer, Contrast Agents
Kenneth P. Olive, Ph.D.
Assistant Professor of Medicine and Pathology & Cell Biology, Columbia University, New York, NY
Results. Driven. Solutions.
Discover how compact, high-performance MRI solutions from Aspect Imaging can deliver powerful results for you.